Hyphens Pharma
Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical group that distributes European and US principals' products across 5 ASEAN countries and develops proprietary dermatology brands (Ceradan, TDF, CG 210), serving hospitals, clinics, retail pharmacies and healthcare professionals.
- Company typePublic
- Founded1989
- HeadquartersWoodlands, Singapore
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hyphens Pharma does
Hyphens Pharma Pte Ltd is a Singapore-headquartered specialty pharmaceutical group (parent: Hyphens Pharma International Limited; SGX Catalist: 1J5) that operates across 5 directly-served ASEAN markets (Singapore, Malaysia, Vietnam, Indonesia, Philippines) and reaches a further 10 countries via distribution partners, with a field force of approximately 330 sales and marketing professionals. The group runs three business pillars: (i) Specialty Pharma Principals — exclusive distribution, licensing and supply agreements with European and US brand principals (including Bausch+Lomb, Chiesi, Guerbet, HRA Pharma, Lundbeck, MEDICE, Daewoong, and others) covering therapeutic areas such as dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, gastroenterology, and child psychiatry; (ii) Proprietary Brands — developed, marketed and sold dermatological products under the Ceradan (including patented Ceradan Advanced pH Management) and TDF Derma Formula lines, scalp-care products under CG 210 (acquired from Legacy Healthcare), and health supplements under Ocean Health, with several technologies (Meradan microemulsion, Xcelarev delivery, Hi-Pure botulinum toxin A) co-developed or licensed with A*STAR; and (iii) Medical Hypermart and Digital — operated through DocMed Technology, supplying pharmaceutical products and medical supplies to healthcare professionals, institutions and retail pharmacies. Founded with early operations in Vietnam in 1989, the group has subsequently expanded to Malaysia (2004), Philippines (2007), Indonesia (2011), and into Middle East markets via a Cooper Pharma partnership for Ceradan in 2024 and an exclusive MC2 Therapeutics licence for Wynzora Cream across ASEAN in 2024. Reported group revenue was SGD 162.3 million in 2022.
The business model combines licensing/royalty economics on distributed principals, branded OTC/Rx product economics on proprietary dermatology and supplement lines, and B2B transaction fees through the DocMed medical hypermart. Go-to-market is enterprise field sales targeting hospitals, clinics, retail pharmacies and healthcare professionals across Southeast Asia, supplemented by exclusive third-party distributors in non-direct markets such as Mainland China, South Korea and the Middle East. Proprietary product differentiation relies on patented formulation technologies, clinical study evidence (e.g., Ceradan Advanced pH-control mechanism, TDF Blu Voile sunscreen cellular-level blue light protection, Meradan co-developed microemulsion), and trademarks granted across multiple jurisdictions. Strategic R&D is conducted through ongoing collaborations with A*STAR (ICES and A*ccelerate units) on microemulsion and dermatological R&D, while licensing-led growth has been the principal route for pipeline additions (Nabota botulinum toxin A, Ustekinumab biosimilar, Wynzora psoriasis cream).
Hyphens Pharma firmographics
Firmographics- Name
- Hyphens Pharma
- Legal name
- Hyphens Pharma Pte Ltd
- Website
- https://hyphens.com.sg
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical group that distributes European and US principals' products across 5 ASEAN countries and develops proprietary dermatology brands (Ceradan, TDF, CG 210), serving hospitals, clinics, retail pharmacies and healthcare professionals.
- Ownership category
- akta.pro rank
Hyphens Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals Distribution
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Hyphens Pharma is headquartered
LocationHeadquarters
- HQ city
- Woodlands
- HQ country
- Singapore
- HQ region
- Asia
Offices6 records
Markets served
Hyphens Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Specialty Pharma Principals: Marketing and selling specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States. Major products include contrast media, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose and Piascledine.
- Proprietary Brands: Develops, markets and sells proprietary dermatological products under Ceradan and TDF brands, health supplements under Ocean Health brand, and scalp care products under CG 210 brand.
- Medical Hypermart and Digital: Operates medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies to supply pharmaceutical products and medical supplies.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Hyphens Pharma product offering
Product offeringCore offering
Hyphens Pharma is a specialty pharmaceutical company that markets and distributes pharmaceutical products across ASEAN through exclusive distribution and licensing agreements with brand principals from Europe and the United States, while also developing, manufacturing, and selling proprietary dermatological brands such as Ceradan, TDF Derma Formula, and CG 210. Its portfolio spans dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, and gastroenterology.
Product overview
Hyphens Pharma is a specialty pharmaceutical company operating as both a distributor of international pharmaceutical brands and a developer of proprietary products. The company distributes specialty pharmaceutical products through exclusive distributorship or licensing agreements with brand principals from Europe and the United States, including products from Bausch + Lomb, Chiesi Farmaceutici, Guerbet Group, HRA Pharma, Lundbeck, and others across therapeutic areas including dermatology, ophthalmology, paediatrics, pulmonology, neuroscience, radiology, and gastroenterology. Additionally, Hyphens Pharma develops and markets proprietary dermatological products under the Ceradan® brand (including Ceradan® Advanced), TDF Derma Formula® brand (including TDF® Blu Voile Sunscreen), and CG 210® brand for hair loss. The company also sells health supplements under the Ocean Health® brand. Products are distributed across Southeast Asia through direct operations in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines.
Differentiator
Problem solved
Functional benefit
Brands
- Ceradan: Dermatological brand - Complete Emollient Therapy delivering physiological lipids in 3:1:1 ratio for optimum skin barrier repair. Focus on eczema-prone skin conditions.
- TDF Derma Formula
- CG 210
- Ocean Health
- DocMed Technology
Products and services
- Ceradan Proprietary dermatological brand featuring Complete Emollient Therapy delivering physiological lipids in the 3:1:1 ratio for optimum skin barrier repair, including skin barrier repair cream and Ceradan Advanced for eczema-prone skin. For healthcare professionals and consumers across ASEAN and Middle East.
- TDF Derma Formula Proprietary dermatological brand including TDF Blu Voile Sunscreen (with clinically-proven 82% blue light protection) and TDF Fairence T-Complex for pigmentation treatment using tranexamic acid, niacinamide, and lactobionic acid. For dermatologists, aesthetic clinics, and patients.
- CG 210 Proprietary topical botanical hair growth-promoting agent based on Allium cepa (onion), Citrus medica limonum (lemon), Theobroma cacao (cocoa), and Paullinia cupana (guarana). Safety and efficacy demonstrated in more than 10 clinical studies involving close to 800 subjects. For Singapore and Malaysia markets.
- Meradan Cream Steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide. Developed with A*STAR using patented microemulsion technology for skin barrier repair. Treats inflammation and itch from eczema, psoriasis, and skin rash. For prescription use in Indonesia and other markets.
- Wynzora Cream Leading topical treatment for plaque and scalp psoriasis in adults. Exclusive ASEAN rights from MC2 Therapeutics. Currently also marketed in Italy, Germany, Spain, United Kingdom, and United States.
- Nabota Premium high-purity botulinum toxin A (BTA) formulated from Daewoong Pharmaceutical's patented Hi-Pure technology. Licensed for Singapore and Malaysia markets for medical aesthetics and therapeutic applications.
- Ustekinumab Biosimilar Human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23) for treatment of immune-mediated disorders including plaque psoriasis, psoriatic arthritis, and Crohn's disease. Produced by Alvotech, distributed in Singapore, Malaysia, and Philippines.
- MAGNEZIX Magnesium alloy metallic implant manufactured by Syntellix AG that can be reabsorbed by the body, enabling quicker and safer bone recovery without need for surgical removal. For orthopaedic surgery in Vietnam.
- Specialty Pharma Principals Distribution Portfolio Distribution of specialty pharmaceutical products across dermatology, ophthalmology, paediatrics, neonatology, pulmonology, neuroscience, psychiatry, allergy, otorhinolaryngology, radiology, and cardiology, sourced through exclusive distributorship or licensing and supply agreements with brand principals from Europe and the United States. Includes Besivance, Lotemax, Stérimar, Vivomixx, Fenosup Lidose, Piascledine, Lexapro, Lipiodol, Dotarem, Xenetix, Curosurf, Medikinet MR, Clopixol, Fluanxol, Fluoxetine, D-Cure, Erdomed, Cetraxal, Dorithricin, Rupafin, Liposic, Ocuvite, Monoclarium, and ella.
- Ocean Health
Quantifiable outcome
- TDF Blu Voile Sunscreen provides 82% protection at cellular level against harmful blue light irradiation
- +3 more outcomes
Companies that use Hyphens Pharma
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Hyphens Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Hyphens Pharma partnerships and signals
Strategic signalPartnerships
25 partnerships are on record, tiered core, strategic and regional.
- Cooper PharmacorePartnership to bring Ceradan dermatological brand to Middle East markets including Saudi Arabia, UAE, Kuwait, Qatar and Bahrain for eczema relief products.
- MC2 TherapeuticscoreHyphens Pharma awarded exclusive rights to commercialise and supply Wynzora Cream (topical treatment for plaque and scalp psoriasis) and all future product extensions throughout ASEAN. Wynzora is currently marketed in Italy, Germany, Spain, UK and US.
- Daewoong PharmaceuticalcoreLicense and supply agreement to bring Nabota premium botulinum toxin A to Malaysian and Singapore markets. Nabota uses Daewoong's patented Hi-Pure technology and is the first Asian BTA approved by US FDA with over 1 million treatments in US since 2019.
- A*STAR (Agency for Science, Technology and Research)strategicJoint development of Meradan cream with patented microemulsion technology containing mometasone furoate and physiological lipids for skin barrier repair.
- Favorex Pte Ltd (DKSH subsidiary)coreExclusive license and supply agreement to commercialise Ustekinumab biosimilar (human monoclonal antibody targeting IL-12 and IL-23) produced by Alvotech in Singapore, Malaysia and Philippines for treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease.
- JSPharmaregionalExclusive distributor of TDF Fairence T-Complex in South Korea. Key customers include medical clinics, hospitals, and burn centres covering dermatologists, plastic surgeons and aesthetic doctors.
- Shanghai Good Luck International Trading Co. Ltd.regionalExclusive distributor of Ceradan products (except Ceradan Advanced) in Mainland China with integrated marketing capability to sell in medical channel across major economic regions.
- Syntellix AGregionalExclusive distributor for Syntellix AG products in Vietnam, including MAGNEZIX bioabsorbable magnesium alloy metallic implants for bone recovery.
- LundbeckcoreExclusive distribution agreement for marketing and distribution of central nervous system products in Vietnam market. Lundbeck is a global pharmaceutical company specializing in brain disease treatment.
- A*STAR A*cceleratestrategicMoU for R&D collaboration on dermatological products for skin disorders targeting eczema, acne and pigmentary disorders. Builds on prior partnership with A*STAR.
- Doctor AnywherestrategicEntry into Memorandum of Understanding with Doctor Anywhere for potential collaboration in digital healthcare services.
- A*STAR Institute of Chemical and Engineering Sciences (ICES)strategicLicensing of sugar-based surfactant micro-emulsions technology from A*STAR for development of innovative dermatological products. Resulted from Research Collaboration Agreement.
- Bausch + LombcorePrincipal partner for eye care products including Besivance and Lotemax.
- Chiesi Farmaceutici S.p.A.corePrincipal partner for specialty pharmaceutical products.
- Guerbet GroupcorePrincipal partner for contrast media products including Dotarem and Xenetix.
- HRA PharmacorePrincipal partner for specialty pharmaceutical products including ella emergency contraceptive.
- Laboratoires ExpansciencecorePrincipal partner for dermatological and consumer healthcare products.
- Laboratoires S.M.BcorePrincipal partner for specialty pharmaceutical products.
- Laboratorios SALVAT S.A.corePrincipal partner for specialty pharmaceutical products.
- MEDICE Arzneimittel Putter GmbH & Co KGcorePrincipal partner for specialty pharmaceutical products including Medikinet for ADHD treatment.
- Next Gen PharmacorePrincipal partner for specialty pharmaceutical products.
- Sofibel - Laboratoires Fumouze (Church & Dwight Group)corePrincipal partner for specialty pharmaceutical products.
- UriachcorePrincipal partner for specialty pharmaceutical products including Rupafin.
- P.T. Nicholas LaboratoriesregionalPartnership for regulatory, logistics and commercial operations in Indonesia since 2011.
- P.T. Kebayoran PharmaregionalPartnership for regulatory, logistics and commercial operations in Indonesia since 2011.
Scale indicators6 records
Recent moves9 records
Expansion highlights7 records
Hyphens Pharma competitors and assessment
Company assessmentBroad incumbents
- Pierre Fabre: French pharmaceutical and dermo-cosmetic company with strong dermatology portfolio and a French/European principal partner model similar to how Hyphens distributes European pharma brands. Overlapping therapeutic focus in dermatology.
- Galderma: Global dermatology-focused pharmaceutical company with a broad prescription and aesthetic dermatology portfolio. Relevant because both companies compete in dermatology therapeutics; Galderma is a global incumbent while Hyphens operates regionally.
- LEO Pharma: Global specialty pharma company focused on dermatology (psoriasis, eczema, actinic keratosis). Comparable therapeutic-area focus to Hyphens' proprietary brands; LEO is a multinational incumbent while Hyphens is regional.
- Bayer Consumer Health (Dermatology): Global consumer health major with a substantial dermatology and skincare portfolio. Comparable as a principal-style brand owner that competes with Hyphens' distributed and proprietary dermatology brands.
Regional players
- Haw Par Corporation: Singapore-listed healthcare company with proprietary brands (Tiger Balm) and regional distribution. Comparable as a Singapore-listed specialty pharma/consumer health peer of similar scale with regional Asia presence.
- Yuhan Corporation: South Korea-listed pharmaceutical company with branded prescription and OTC products including dermatology offerings. Comparable as an Asia-headquartered specialty pharma player with both proprietary and distribution-style operations.
- EuroMed Laboratories Philippines: Philippines-listed pharmaceutical company manufacturing and distributing branded generics and consumer health products in ASEAN. Comparable as a regional pharma player with similar distribution-led model.
Others
- Siegfried Holding: Swiss pharmaceutical CDMO that supplies APIs and finished dosage forms to global pharma including dermatology brands. Comparable as an enabling partner within the European-to-Asia pharmaceutical value chain that intersects with Hyphens' principal sourcing model.
Direct peers
- Zuellig Pharma: One of the largest healthcare distribution groups in Asia, distributing pharmaceuticals and consumer health products across ASEAN markets. Direct comparable to Hyphens' Principals and Medical Hypermart segments given overlapping customer base and similar distribution contracts with global pharma principals.
- DKSH Holding: Swiss-listed market expansion services group with the largest healthcare distribution platform in ASEAN. Both companies operate as principal intermediaries distributing Western pharma brands across Southeast Asia, with overlapping regional coverage and similar go-to-market models.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Hyphens Pharma social profiles
Digital presenceHyphens Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hyphens Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Hyphens Pharma subsidiaries and ownership
Company hierarchySubsidiaries7 records
Hyphens Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hyphens Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hyphens Pharma
What does Hyphens Pharma do?
Hyphens Pharma is a specialty pharmaceutical company that markets and distributes pharmaceutical products across ASEAN through exclusive distribution and licensing agreements with brand principals from Europe and the United States, while also developing, manufacturing, and selling proprietary dermatological brands such as Ceradan, TDF Derma Formula, and CG 210. Its portfolio spans dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, and gastroenterology.
Is Hyphens Pharma a public or private company?
Hyphens Pharma is a public company. It is classified as public and is currently operating.
When was Hyphens Pharma founded?
Hyphens Pharma was founded in 1989. It employs 101 to 250 people.
Where is Hyphens Pharma based?
Hyphens Pharma is headquartered in Woodlands, Singapore, in the Asia region.
How does Hyphens Pharma make money?
Three revenue lines are on record. Specialty Pharma Principals are the primary driver. The others are proprietary Brands and medical Hypermart and Digital.
Who are Hyphens Pharma's main competitors?
Broad incumbents on record are Pierre Fabre, Galderma, LEO Pharma and Bayer Consumer Health (Dermatology). Regional players are Haw Par Corporation, Yuhan Corporation and EuroMed Laboratories Philippines. Siegfried Holding is listed as an others. Direct peers are Zuellig Pharma and DKSH Holding.
Does Hyphens Pharma have an API?
No public API is recorded for Hyphens Pharma.
What industry is Hyphens Pharma in?
Hyphens Pharma's product category is Specialty Pharmaceuticals Distribution. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.